MGMT Promoter Methylation and Parathyroid Carcinoma

Area of Science:

• Oncology
• Genetics
• Endocrinology

Background:

• Parathyroid carcinoma (PC) is a rare endocrine malignancy with a poor prognosis.
• Currently, no evidence-based systemic therapies exist for advanced PC.
• Previous research indicated a complete remission in a patient with metastatic PC and high MGMT promoter methylation treated with temozolomide.

Purpose of the Study:

• To investigate the MGMT promoter methylation status in a cohort of aggressive parathyroid tumors.
• To explore the potential role of MGMT methylation in predicting response to temozolomide therapy in PC.

Main Methods:

• Analyzed MGMT promoter methylation status in 12 patients with aggressive parathyroid tumors (11 PC, 1 atypical adenoma).
• Tumor DNA was extracted from primary or metastatic samples.
• High MGMT promoter methylation was defined as a mean methylation level >20%.

Main Results:

• Only one previously reported patient exhibited high MGMT promoter methylation.
• The atypical parathyroid adenoma did not show high MGMT methylation.
• A patient with disseminated PC and a CDC73 deletion had low MGMT methylation but stable disease after temozolomide treatment.

Conclusions:

• High MGMT promoter methylation appears to be uncommon in parathyroid carcinoma.
• Temozolomide may offer a therapeutic benefit for select patients with disseminated PC, similar to other neuroendocrine tumors.
• MGMT promoter methylation status could serve as a predictive biomarker for temozolomide treatment efficacy in PC.